Resveratrol and Cardiovascular Diseases

Area of Science:

• Cardiovascular Research
• Nutraceuticals and Dietetics

Background:

• Cardiovascular diseases (CVDs) represent a growing global health concern, driving research into preventative and therapeutic compounds.
• Resveratrol (RES), a polyphenol from grapes and red wine, is investigated for its potential cardioprotective effects, linked to the "French paradox".
• RES exhibits antioxidant and anti-inflammatory properties, including scavenging free radicals and upregulating endothelial NO synthase (eNOS).

Purpose of the Study:

• To explore the molecular mechanisms and potential benefits of resveratrol (RES) in mitigating cardiovascular diseases (CVDs).
• To evaluate RES's role in improving endothelial function by influencing nitric oxide (NO) availability and oxidative stress.
• To critically assess the translation of preclinical findings to human clinical trials for RES in CVD management.

Main Methods:

• Review of preclinical studies investigating RES's antioxidant, anti-inflammatory, and endothelial function-modulating effects.
• Analysis of RES's impact on key molecular targets such as SIRT-1, AMPK, Nrf2, and NFκB.
• Examination of the discrepancy between high-dose RES in research and low concentrations in dietary sources like red wine.

Main Results:

• RES demonstrates significant antioxidant capacity by scavenging reactive oxygen species (ROS) and limiting lipid peroxidation.
• In vitro studies show RES can restore dimethylargininedimethylaminohydrolase (DDAH) activity, counteracting asymmetric dimethylarginine (ADMA) and enhancing nitric oxide (NO) production.
• Preclinical data suggest RES targets pathways involved in cellular protection and inflammation relevant to CVDs.

Conclusions:

• Resveratrol shows potential for improving cardiovascular health through antioxidant and anti-inflammatory mechanisms, particularly by enhancing endothelial function.
• The discrepancy in RES concentrations between preclinical studies and dietary intake complicates direct clinical application and interpretation.
• Further well-designed human clinical trials are essential to validate the therapeutic efficacy of RES for various cardiovascular diseases (CVDs).